Reference Cases



How Curium & NRG managed to be the first in Europe to stop using high enriched uranium for the production of molybdenum-99.


Successful partnerships led to new innovative processes.


How McMaster & NRG joined forces to guarantee a worldwide reliable delivery of iodine-125.

A few of our success stories

17 May 2024

Being able to predict which cancer patient is likely to respond to chemotherapy with cisplatin has not yet been possible. However, a unique research project between NRG|PALLAS, the Netherlands Cancer Institute (NKI) and Amsterdam UMC may bring about some change.

29 July 2020

Producing medical isotopes using only low enriched uranium? After a challenging design process, Curium and NRG are the first in Europe to produce molybdenum-99 with low enriched uranium. Recognizing the commitments made during the Nuclear Summit 2014, to phase out high enriched uranium (HEU) based medical isotopes.

22 July 2020

Recently, we have developed the world’s first fully automated synthesis module, for the synthesis of Pt-195m cisplatin and other platinum compounds

21 July 2020

A complex project has been brought to a successful conclusion: the development and installation of a production process for xenon-133 gas.

26 May 2020

In 2017, there was suddenly a worldwide shortage of iodine-125, used for brachytherapy for prostate cancer, because one of the large producers was temporarily shut down. McMaster & NRG joined forces for global supply.